Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 4,802 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sensitivity Clear all
Completed Phase 2 Interventional

Culturally Sensitive Depression Care Management for Latino Primary Care Patients

NCT00571454
View directory record Official record
Conditions
Depression
Interventions
telephone depression care management
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 30, 2009 · Synced Oct 23, 2026, 12:52 AM EDT
Completed Not applicable Interventional Results available

Effectiveness of the Aeroneb in Acute Severe Asthma

NCT03029156
View directory record Official record
Conditions
Asthma Exacerbation
Interventions
Aeroneb nebulizer, Small volume jet nebulizer
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 23, 2026, 12:52 AM EDT
Completed Phase 2 Interventional Results available

Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT01859988
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 23, 2026, 12:52 AM EDT
Completed Phase 2 Interventional

Treating Exacerbations of Asthma With Oral Montelukast in Children

NCT05819541
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Montelukast Oral Granules, Albuterol, Corticosteroid
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
4 Years to 12 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 23, 2026, 12:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis

NCT04668066
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-07242813, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
7
States / cities
Anaheim, California • Fountain Valley, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 23, 2026, 12:52 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

NCT04133922
View directory record Official record
Conditions
Type 1 Diabetes, Insulin Sensitivity/Resistance
Interventions
GLP-1, Insulin, Dextrose 20 % in Water
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 23, 2026, 12:52 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adolescents

NCT02499705
View directory record Official record
Conditions
Insulin Resistance, Obesity
Interventions
Sucralose, Sucrose, Sucralose + maltodextrin
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
13 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 23, 2026, 12:52 AM EDT
Completed No phase listed Observational

Delta Primary Care Provider (PCP) Survey on Asthma Management

NCT00955656
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 23, 2026, 12:52 AM EDT
Completed No phase listed Observational

Research in Skin Inflammation

NCT00026741
View directory record Official record
Conditions
Psoriasis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 12:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CES1 Carriers in the PAPI Study

NCT03188705
View directory record Official record
Conditions
Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases, Myocardial Ischemia, Artery Occlusion, Aspirin Sensitivity, Clopidogrel, Poor Metabolism of, Platelet Dysfunction, Platelet Thrombus
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 12:52 AM EDT
Active, not recruiting Phase 2 Interventional

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

NCT05186753
View directory record Official record
Conditions
SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis, ISM, BMM, Smoldering Systemic Mastocytosis, Bone Marrow Mastocytosis
Interventions
Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 12:52 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies

NCT01368445
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
azelastine hydrochloride 0.15% Nasal Spray, azelastine hydrochloride 0.15% and Placebo, Azelastine 0.1%, Nasal Spray
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
30
States / cities
Fountain Valley, California • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2011 · Synced Oct 23, 2026, 12:52 AM EDT
Recruiting Not applicable Interventional

Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis

NCT07588672
View directory record Official record
Conditions
Seasonal Allergic Rhinitis (SAR), Allergic Rhinitis
Interventions
PL-14 Allergy Blocker, Ayr® Saline Nasal Mist
Device
Lead sponsor
Polyrizon Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Normal, Illinois • St Louis, Missouri • Ocean City, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 12:52 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

NCT05795153
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Little Rock, Arkansas • Aventura, Florida • Greenacres City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 23, 2026, 12:52 AM EDT
Completed Phase 3 Interventional Results available

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

NCT04444895
View directory record Official record
Conditions
Angioedema
Interventions
Lanadelumab
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Oct 23, 2026, 12:52 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Sleep Extension on Ceramides in People With Overweight and Obesity

NCT06180837
View directory record Official record
Conditions
Lifestyle Factors, Overweight and Obesity, Insulin Sensitivity, Eating Habit, Sleep Hygiene, Type 2 Diabetes, Sleep, Sleep Deprivation, Insufficient Sleep Syndrome
Interventions
Sleep Extension Intervention
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 23, 2026, 12:52 AM EDT
Completed Not applicable Interventional

Affect Treatment for Depression and Anxiety

NCT05203861
View directory record Official record
Conditions
Depression, Anxiety
Interventions
Positive Affect Treatment, Negative Affect Treatment
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 23, 2026, 12:52 AM EDT
Completed Phase 2 Interventional

A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)

NCT01275105
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%, Oxymetazoline HCl 0.025%
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 23, 2026, 12:52 AM EDT
Completed Phase 2 Interventional

Study of Oglemilast for the Prevention of Asthma.

NCT00322283
View directory record Official record
Conditions
Exercise-Induced Asthma
Interventions
Oglemilast, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Los Angeles, California • North Dartmouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Oct 23, 2026, 12:52 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE

NCT00914966
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 inhibitor (human) [C1 INH]
Biological
Lead sponsor
Shire
Industry
Eligibility
6 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Wheaton, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 23, 2026, 12:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treating the Endothelium to Restore Insulin Sensitivity

NCT00402194
View directory record Official record
Conditions
Obesity, Insulin Resistance, Impaired Glucose Tolerance, Pre-diabetes
Interventions
Losartan
Drug
Lead sponsor
Indiana University
Other
Eligibility
20 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 24, 2013 · Synced Oct 23, 2026, 12:52 AM EDT
Completed Not applicable Interventional Results available

Breathing Counts: Evaluating Adherence in the Presence of Asthma Navigation Support

NCT03065205
View directory record Official record
Conditions
Asthma
Interventions
Propeller Health device + asthma navigator
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 23, 2026, 12:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)

NCT02870205
View directory record Official record
Conditions
Seasonal Allergic Rhinitis (SAR)
Interventions
GSP 301 NS, GOM-NS, GMM-2 NS, GSP 301 placebo NS
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
12 Years and older
Enrollment
1,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
43
States / cities
Mission Viejo, California • Orange, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 23, 2026, 12:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

ADRN Barrier/Immunoprofiling Exploratory Pilot Study

NCT02115399
View directory record Official record
Conditions
Dermatitis, Dermatitis, Atopic, Eczema, Non-atopic Healthy Controls
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Denver, Colorado • Rochester, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Oct 23, 2026, 12:52 AM EDT